On July 29, Boston Scientific rose 3.13% in pre-market trading to $47.48 per share, with turnover of $365,500. The move comes as the company releases its Q2 earnings report before market open, with multiple catalysts converging to lift sentiment.

Market consensus expects quarterly revenue of approximately $5.364 billion, representing 9.63% year-over-year growth, with adjusted EPS of $0.83, up 14.13% year-over-year. UBS lowered its price target from $95 to $74 but maintained its Buy rating, emphasizing that the stock has underappreciated growth drivers beyond electrophysiology and Watchman. The firm highlighted coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion served market, along with the Empower leadless pacemaker launch. UBS noted current share pricing implies sales declines through 2029, a scenario the firm views as overly pessimistic.

Additionally, Boston Scientific disclosed a global restructuring plan expected to incur $700-800 million in pre-tax charges while achieving approximately $500 million in annual cost savings, with substantial completion targeted by end of 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)